Isoform selectivity of adenylyl cyclase inhibitors: Characterization of known and novel compounds

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 2, 2013, Pages 265-275

  Brand, Cameron S ^a   Hocker, Harrison J ^a   Gorfe, Alemayehu A ^a   Cavasotto, Claudio N ^b,c   Dessauer, Carmen W ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Instituto de Investigación en Biomedicina de Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; CYCLIC AMP; FORSKOLIN; ISOENZYME; NB 001; NKY 80; NKY80; UNCLASSIFIED DRUG; VIDARABINE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; DRUG BINDING SITE; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ADENYLATE CYCLASE; ANIMALS; BINDING SITES; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP; DRUG DISCOVERY; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; ISOENZYMES; MOLECULAR DOCKING SIMULATION; PLASMIDS; RATS; SF9 CELLS; SMALL MOLECULE LIBRARIES; SPODOPTERA; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 84885974268     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208157     Document Type: Article

References (68)

1. Aldehni F, Tang T, Madsen K., Plattner M, Schreiber A, Friis U.G., Hammond HK, Han PL, and Schweda F (2011) Stimulation of renin secretion by catecholamines is dependent on adenylyl cyclases 5 and 6. Hypertension 57:460-468.
2. Antos CL, Frey N, Marx S.O., Reiken S., Gaburjakova M, Richardson JA, Marks A.R., and Olson EN (2001) Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ Res 89:997-1004.
3. Bai Y, Tsunematsu T, Jiao Q., Ohnuki Y, Mototani Y, Shiozawa K., Jin M, Cai W, Jin HL, and Fujita T, et al. (2012) Pharmacological stimulation of type 5 adenylyl cyclase stabilizes heart rate under both microgravity and hypergravity induced by parabolic flight. J Pharmacol Sci 119:381-389.
4. Bauman AL, Soughayer J, Nguyen B.T., Willoughby D., Carnegie GK, Wong W, Hoshi N, Langeberg L.K., Cooper DM, and Dessauer CW, et al. (2006) Dynamic regulation of cAMP synthesis through anchored PKA-adenylyl cyclase V/VI complexes. Mol Cell 23:925-931.
5. Braeunig JH, Schweda F, Han P.L., and Seifert R (2013) Similarly potent inhibition of adenylyl cyclase by P-site inhibitors in hearts from wild type and AC5 knockout mice. PLoS ONE 8:e68009.
6. Bristow MR, Ginsburg R, Minobe W., Cubicciotti RS, Sageman WS, Lurie K, Billingham M.E., Harrison DC, and Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307:205-211.
7. Brunskole Hummel I., Reinartz MT, Kälble S, Burhenne H., Schwede F, Buschauer A, and Seifert R (2013) Dissociations in the Effects of β2-Adrenergic Receptor Agonists on cAMP Formation and Superoxide Production in Human Neutrophils: Support for the Concept of Functional Selectivity. PLoS ONE 8:e64556.
8. Cavasotto CN, Orry AJ, Murgolo N.J., Czarniecki MF, Kocsi SA, Hawes BE, O'Neill KA, Hine H, Burton MS, and Voigt JH, et al. (2008) Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem 51:581-588.
9. Cavasotto CN and Singh N (2008) Docking and high throughput docking: successes and the challenge of protein flexibility. Curr Comput Aided Drug Design 4:221-234.
10. Chen-Goodspeed M., Lukan AN, and Dessauer CW (2005) Modeling of Galpha(s) and Galpha(i) regulation of human type V and VI adenylyl cyclase. J Biol Chem 280: 1808-1816.
11. Chen L, Marquardt ML, Tester D.J., Sampson KJ, Ackerman MJ, and Kass RS (2007) Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci USA 104:20990-20995.
12. Dessauer CW (2002) Kinetic analysis of the action of P-site analogs. Methods Enzymol 345:112-126.
13. Dessauer CW, Tesmer JJ, Sprang S.R., and Gilman AG (1999) The interactions of adenylate cyclases with P-site inhibitors. Trends Pharmacol Sci 20:205-210.
14. Efendiev R and Dessauer CW (2011) A kinase-anchoring proteins and adenylyl cyclase in cardiovascular physiology and pathology. J Cardiovasc Pharmacol 58:339-344.
15. Emery AC, Eiden MV, and Eiden LE (2013) A new site and mechanism of action for the widely used adenylate cyclase inhibitor SQ22,536. Mol Pharmacol 83:95-105.
16. Engelhardt S, Hein L, Wiesmann F., and Lohse MJ (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96:7059-7064.
17. Erdorf M, Mou TC, and Seifert R (2011) Impact of divalent metal ions on regulation of adenylyl cyclase isoforms by forskolin analogs. Biochem Pharmacol 82:1673-1681.
18. Espinasse I, Iourgenko V, Defer N., Samson F, Hanoune J, and Mercadier JJ (1995) Type V, but not type VI, adenylyl cyclase mRNA accumulates in the rat heart during ontogenic development. Correlation with increased global adenylyl cyclase activity. J Mol Cell Cardiol 27:1789-1795.
19. Fagan KA, Mahey R, and Cooper DM (1996) Functional co-localization of transfected Ca(2+)-stimulable adenylyl cyclases with capacitative Ca2+ entry sites. J Biol Chem 271:12438-12444.
20. Feldman MD, Copelas L, Gwathmey J.K., Phillips P., Warren SE, Schoen FJ, Grossman W, and Morgan JP (1987) Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure. Circulation 75:331-339.
21. Gatica EA and Cavasotto CN (2012) Ligand and decoy sets for docking to G protein-coupled receptors. J Chem Inf Model 52:1-6.
22. Gille A and Seifert R (2003) 29(39)-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors. J Biol Chem 278:12672-12679.
23. Grant BJ, Lukman S, Hocker H.J., Sayyah J., Brown JH, McCammon JA, and Gorfe AA (2011) Novel allosteric sites on Ras for lead generation. PLoS ONE 6:e25711.
24. Ho D, Yan L, Iwatsubo K., Vatner DE, and Vatner SF (2010) Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5. Heart Fail Rev 15:495-512.
25. Hoshi N, Langeberg LK, Gould C.M., Newton AC, and Scott JD (2010) Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol Cell 37:541-550.
26. Huey R, Morris GM, Olson A.J., and Goodsell DS (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28:1145-1152.
27. Humphrey W, Dalke A and Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38, 27-38.
28. Iwase M, Uechi M, Vatner D.E., Asai K., Shannon RP, Kudej RK, Wagner TE, Wight D.C., Patrick TA, and Ishikawa Y, et al. (1997) Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Physiol 272:H585-H589.
29. Iwatsubo K, Bravo C, Uechi M., Baljinnyam E, Nakamura T, Umemura M., Lai L, Gao S, Yan L, and Zhao X, et al. (2012) Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase. Am J Physiol Heart Circ Physiol 302:H2622-H2628.
30. Iwatsubo K, Minamisawa S, Tsunematsu T., Nakagome M, Toya Y, Tomlinson J.E., Umemura S., Scarborough RM, Levy DE, and Ishikawa Y (2004) Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem 279:40938-40945.
31. Johnson RA, Désaubry L, Bianchi G., Shoshani I, Lyons E, Jr, Taussig R, Watson PA, Cali JJ, Krupinski J, and Pieroni JP, et al. (1997) Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 39-polyphosphates. J Biol Chem 272:8962-8966.
32. Kapiloff MS, Piggott LA, Sadana R, Li J., Heredia LA, Henson E, Efendiev R, and Dessauer CW (2009) An adenylyl cyclase-mAKAPbeta signaling complex regulates cAMP levels in cardiac myocytes. J Biol Chem 284:23540-23546.
33. Kim KS, Kim J, Back S.K., Im JY, Na HS, and Han PL (2007) Markedly attenuated acute and chronic pain responses in mice lacking adenylyl cyclase-5. Genes Brain Behav 6:120-127.
34. Kim KS, Lee KW, Lee K.W., Im JY, Yoo JY, Kim SW, Lee J.K., Nestler EJ, and Han PL (2006) Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. Proc Natl Acad Sci USA 103:3908-3913.
35. Lai NC, Roth DM, Gao M.H., Fine S., Head BP, Zhu J, McKirnan MD, Kwong C, Dalton N., and Urasawa K, et al. (2000) Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation 102:2396-2401.
36. Lai NC, Roth DM, Gao M.H., Tang T., Dalton N, Lai YY, Spellman M, Clopton P., and Hammond HK (2004) Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 110:330-336.
37. Li Y, Chen L, Kass R.S., and Dessauer CW (2012) The A-kinase anchoring protein Yotiao facilitates complex formation between adenylyl cyclase type 9 and the IKs potassium channel in heart. J Biol Chem 287:29815-29824.
38. Marx SO, Kurokawa J, Reiken S., Motoike H, DArmiento J, Marks A.R., and Kass RS (2002) Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 295: 496-499.
39. Morris GM, Huey R, Lindstrom W., Sanner MF, Belew RK, Goodsell DS, and Olson AJ (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30:2785-2791.
40. Mou TC, Gille A, Fancy D.A., Seifert R., and Sprang SR (2005) Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2 '(3')-O-(N-Methylanthraniloyl)-guanosine 5 '-triphosphate. J Biol Chem 280:7253-7261.
41. Mou TC, Gille A, Suryanarayana S., Richter M, Seifert R, and Sprang SR (2006) Broad specificity of mammalian adenylyl cyclase for interaction with 29,39-substituted purine- and pyrimidine nucleotide inhibitors. Mol Pharmacol 70: 878-886.
42. Mou TC, Masada N, Cooper D.M., and Sprang SR (2009) Structural basis for inhibition of mammalian adenylyl cyclase by calcium. Biochemistry 48:3387-3397.
43. Musi N, Hayashi T, Fujii N., Hirshman MF, Witters LA, and Goodyear LJ (2001) AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle. Am J Physiol Endocrinol Metab 280:E677-E684.
44. Okumura S, Takagi G, Kawabe J., Yang G, Lee MC, Hong C, Liu J., Vatner DE, Sadoshima J, and Vatner SF, et al. (2003) Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 100:9986-9990.
45. Okumura S, Vatner DE, Kurotani R, Bai Y., Gao S, Yuan Z, Iwatsubo K., Ulucan C, Kawabe J, and Ghosh K, et al. (2007) Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation 116:1776-1783.
46. Onda T, Hashimoto Y, Nagai M., Kuramochi H, Saito S, Yamazaki H., Toya Y, Sakai I, Homcy CJ, and Nishikawa K, et al. (2001) Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J Biol Chem 276:47785-47793.
47. Ortiz-Capisano M.C., Ortiz PA, Harding P, Garvin J.L., and Beierwaltes WH (2007) Adenylyl cyclase isoform v mediates renin release from juxtaglomerular cells. Hypertension 49:618-624.
48. Pavan B, Biondi C, and Dalpiaz A (2009) Adenylyl cyclases as innovative therapeutic goals. Drug Discov Today 14:982-991.
49. Phan HM, Gao MH, Lai N.C., Tang T., and Hammond HK (2007) New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy. Trends Cardiovasc Med 17: 215-221.
50. Pierre S, Eschenhagen T, Geisslinger G., and Scholich K (2009) Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov 8:321-335.
51. Piggott LA, Bauman AL, Scott J.D., and Dessauer CW (2008) The A-kinase anchoring protein Yotiao binds and regulates adenylyl cyclase in brain. Proc Natl Acad Sci USA 105:13835-13840.
52. Pinto C, Hübner M, Gille A., Richter M, Mou TC, Sprang S.R., and Seifert R (2009) Differential interactions of the catalytic subunits of adenylyl cyclase with forskolin analogs. Biochem Pharmacol 78:62-69.
53. Pluznick JL, Zou DJ, Zhang X, Yan Q., Rodriguez-Gil DJ, Eisner C, Wells E., Greer CA, Wang T, and Firestein S, et al. (2009) Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci USA 106:2059-2064.
54. Rieg T, Tang T, Murray F., Schroth J, Insel PA, Fenton R.A., Hammond HK, and Vallon V (2010) Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla. J Am Soc Nephrol 21:2059-2068.
55. Sadana R and Dessauer CW (2009) Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals 17:5-22.
56. Seifert R, Lushington GH, Mou T.C., Gille A., and Sprang SR (2012) Inhibitors of membranous adenylyl cyclases. Trends Pharmacol Sci 33:64-78.
57. Tang T, Gao MH, Lai N.C., Firth AL, Takahashi T, Guo T, Yuan J.X., Roth DM, and Hammond HK (2008) Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling. Circulation 117:61-69.
58. Tang T, Lai NC, Wright A.T., Gao MH, Lee P, Guo T, Tang R., McCulloch AD, and Hammond HK (2013) Adenylyl cyclase 6 deletion increases mortality during sustained b-adrenergic receptor stimulation. J Mol Cell Cardiol 60: 60-67
59. Taussig R, Tang WJ, Hepler J.R., and Gilman AG (1994) Distinct patterns of bidirectional regulation of mammalian adenylyl cyclases. J Biol Chem 269:6093-6100.
60. Tesmer JJ, Sunahara RK, Gilman A.G., and Sprang SR (1997) Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. Science 278:1907-1916.
61. Tesmer JJ, Sunahara RK, Johnson R.A., Gosselin G., Gilman AG, and Sprang SR (1999) Two-metal-Ion catalysis in adenylyl cyclase. Science 285:756-760.
62. Vadakkan KI, Wang H, Ko S.W., Zastepa E., Petrovic MJ, Sluka KA, and Zhuo M (2006) Genetic reduction of chronic muscle pain in mice lacking calcium/calmodulin-stimulated adenylyl cyclases. Mol Pain 2:7.
63. Villacres EC, Wong ST, Chavkin C, and Storm DR (1998) Type I adenylyl cyclase mutant mice have impaired mossy fiber long-term potentiation. J Neurosci 18:3186-3194.
64. Wang H, Gong B, Vadakkan K.I., Toyoda H., Kaang B-K, and Zhuo M (2007) Genetic evidence for adenylyl cyclase 1 as a target for preventing neuronal excitotoxicity mediated by N-methyl-D-aspartate receptors. J Biol Chem 282:1507-1517.
65. Wang H, Xu H, Wu L.J., Kim SS, Chen T, Koga K, Descalzi G., Gong B, Vadakkan KI, and Zhang X, et al. (2011) Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain. Sci Transl Med 3:ra3.
66. Whitley R, Alford C, Hess F., and Buchanan R (1980) Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs 20:267-282.
67. Yan SZ, Beeler JA, Chen Y, Shelton R.K., and Tang WJ (2001) The regulation of type 7 adenylyl cyclase by its C1b region and Escherichia coli peptidylprolyl isomerase, SlyD. J Biol Chem 276:8500-8506.
68. Zhou M (2012) inventor, University of Toronto, assignee. Method for treating neuronal and non-neuronal pain. U.S. patent 8,124,599. 2012 Dec 12.